Recent Updates
Recently added Catalysts
VCYT Positive Sentiment Score: 70/100

Veracyte to Participate in Upcoming June 2026 Investor Conferences

Key Takeaway: Veracyte, Inc. (Nasdaq: VCYT) has announced its participation in upcoming investor conferences. The company will provide live audio webcasts of its presentations, which will be accessible on their website. This initiative reflects Veracyte's ongoing commitment to engage with investors and showcase its advancements in cancer diagnostics.
Price reaction · baseline $41.69 (2026-05-19 close) · hit pre-market · 2 other VCYT headline(s) in the window, move may be shared
day 0 close · peak
+8.4%
day 1
+8.4%
day 3
+6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Veracyte is actively participating in investor conferences, indicating strong investor engagement.
  • The company showcases its commitment to innovation in cancer diagnostics.
  • Live webcasts and replays enhance accessibility for investors.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences.
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website athttp://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care.Veracyte’s Diagnostics Platformcombines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continuedinnovation and pipeline development. The company’s portfolio includes theAfirma® Genomic Sequencing Classifier test,Decipher® Bladder Genomic Classifier test,Decipher® Prostate Genomic Classifier test,Prosigna® Breast Risk of Recurrence test, and theTrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’swebsiteor follow the company onLinkedInorX (Twitter).

Frequently Asked Questions

What investor conferences will Veracyte participate in?

Veracyte will participate in several investor conferences in June 2026.

How can I access Veracyte's conference presentations?

Live audio webcasts of the presentations will be available on Veracyte's website.

How long will the webcasts be available for replay?

Replays of the webcasts will be accessible for 90 days after each live presentation.

What is Veracyte's focus in cancer care?

Veracyte aims to transform cancer care through its molecular tests and diagnostics.

Last updated: May 20, 2026